Compare Inovio Pharmaceuticals Inc (INO) vs KraneShares CSI China Internet ETF (KWEB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs KraneShares CSI China Internet ETF — how do they compare? Inovio Pharmaceuticals Inc trades at $1.11 (market cap $112.19M), while KraneShares CSI China Internet ETF trades at $24.78 (market cap $4.37B). The key difference: KraneShares CSI China Internet ETF is far larger — about 39× Inovio Pharmaceuticals Inc's market cap, and Inovio Pharmaceuticals Inc is trading nearer its 52-week high, KraneShares CSI China Internet ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and KraneShares CSI China Internet ETF for 57 Days on average.
| INO | KWEB | |
|---|---|---|
Market Cap | $112.19M | $4.37B |
Volume | 3,201,278 | 13,393,361 |
Sector | Health | Sector/Thematic |
52-Week High | $2.65 | $41.35 |
52-Week Low | $0.66 | $23.63 |
Typical Hold Time | 43 Days | 57 Days |
Enterprise Value | $83.51M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals trades at $1.155, up 2.21% today, with a bearish technical signal despite recent earnings beats. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, reflected in a -130,000% net margin. Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis, with analyst consensus leaning bullish at a $2.75 price target.
Investment outlook hinges on FDA approval success; upside exists if INO-3107 gains approval, but persistent cash burn and lack of commercial revenue pose substantial risks. The stock remains speculative with high volatility expected around regulatory milestones.
KWEB trades at $24.87, up 2.22% with bearish technical signals from moving averages and neutral oscillators. Recent news highlights institutional position changes and China-focused economic developments. The ETF faces headwinds from U.S.-China trade dynamics and Chinese industrial overcapacity concerns.
The outlook remains cautious due to geopolitical risks and technical weakness. Investment opportunities exist for those bullish on China's internet sector recovery, but risks include trade tensions and economic rebalancing pressures that could impact performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About KraneShares CSI China Internet ETF
KWEB tracks the CSI Overseas China Internet Index, providing exposure to Chinese software and services companies listed in the US and Hong Kong, including giants like Tencent, Alibaba, and Meituan.
Read more on KWEB →
